Humanin vs Semax
Both Humanin and Semax are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Side-by-Side
| Attribute | Humanin | Semax |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — mitochondrial-derived peptide research compound | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders |
| Typical Dose | Research range: 0.5–1 mg subcutaneous (rare clinical use) | 200–600 mcg intranasal, morning |
| Clinics Indexed | 5 | 89 |
| Categories | mitochondrial, longevity, neuroprotection | cognitive, neuroprotection |
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.